This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
Tri-Heal (45 mg Blend)
This information is for research and educational use only.
Quick Reference
What is Tri-Heal?
Research overview based on the cited scientific literature.
• Goal: Support tissue repair, regeneration, and inflammation modulation through synergistic peptide action[2][3][4].
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw[5].
Storage Instructions
Proper storage preserves peptide quality and potency.
• Lyophilized: Store at −20 °C (−4 °F) or colder (ideally −80 °C / −112 °F for long-term) in dry, dark conditions[5].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks; prepare aliquots if needed and avoid freeze–thaw cycles[5].
• Allow vials to reach room temperature before opening to reduce condensation uptake.
How is Tri-Heal studied?
Tri-Heal combines three peptides with complementary mechanisms targeting multiple aspects of tissue injury repair:
TB-500 (Thymosin β4): Acts as a natural repair factor, inhibiting inflammation and apoptosis while promoting angiogenesis, cell migration, and matrix remodeling[2][7]. This 43-amino-acid peptide has been shown to accelerate dermal healing in both preclinical models and clinical applications[2].
BPC-157 (Body Protection Compound): Enhances healing via VEGFR2/Akt-eNOS activation, increasing nitric oxide production and angiogenesis while stimulating fibroblast activity[8]. This 15-amino-acid gastric peptide accelerates tendon, muscle, and gut repair[3][9].
KPV (Lys-Pro-Val): Provides anti-inflammatory effects by reducing NF-κB activation and attenuating pro-inflammatory cytokine signaling in epithelial and immune cells[4]. This α-MSH-derived tripeptide complements the regenerative actions of TB-500 and BPC-157.
The combination thus addresses wound repair, angiogenesis, and inflammation simultaneously through distinct but synergistic pathways.
What does the research report about Tri-Heal?
Observations from preclinical and clinical literature on the individual components.
• TB-500: Promotes cell proliferation, angiogenesis, and accelerated tissue repair; inhibits apoptosis and inflammation in healing tissues[2][7].
• BPC-157: Accelerates musculoskeletal healing including tendon and muscle repair; stimulates endothelial regeneration and fibroblast activity[3][9].
• KPV: Reduces inflammatory cytokine release; demonstrates efficacy in models of epithelial inflammation[4].
• General tolerability: Individual peptides are generally well tolerated in preclinical studies; occasional mild injection-site reactions (redness, transient discomfort) may occur with subcutaneous administration.
Note: Human clinical data on this specific combination is limited; observations are extrapolated from studies of individual components.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on Tri-Heal?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.
